A protein called TRIM22 can slow some cancers and help others
Original title: TRIM22 in cancer: a context-dependent E3 ligase at the interface of interferon, p53, and tumor plasticity.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a review of lab science, not a new result or something a patient can get.
The short version
Scientists reviewed a protein that seems to hold back some cancers but help others grow, including brain tumors.
What was studied. This is a review paper, not a new experiment. The authors gathered and summed up past lab studies on a protein called TRIM22 across many kinds of cancer.
What they found. In breast, colon, ovarian, womb, liver, cervical, and stomach cancers, TRIM22 levels are often low or not working well. In those cases, putting it back seemed to slow cancer cells from growing and spreading. But in glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary, melanoma, pancreatic cancer, and some lung cancers, TRIM22 often did the opposite and helped the tumor grow and resist drugs. The authors say it acts like a stress switch, and what it does depends on the type of cell it sits in.
What this means, and what it doesn't
What it could mean: For brain tumors, this points to a protein that researchers may want to target someday. For now it is a research idea, not a treatment option.
What it doesn't mean: This is not a new treatment and not a cure. There is no TRIM22 drug being tested in people. The paper is a review of lab science, so it is far from everyday care. It does not change how brain tumors are treated today.
Source: PubMed, October 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.